Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators

A compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof,

• wherein:
• the group X—Y is —NHSO2— or —SO2NH—;
• Z is:
• a monocyclic aryl group, or
• a monocyclic heteroaryl group selected from pyridinyl, thienyl, tetrazoyl, imidazolyl, pyrimidinyl, thiazolyl, pyradizinyl, isothiazolyl, 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, triazinyl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, 1H-pyrrol-4-yl, furanyl, oxazolyl, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl and 1H-1,2,3-triazol-1-yl;
• each of which is optionally substituted by one or more substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH;
• R1 is H, CN or alkyl;
• R2 is selected from COOH and a tetrazolyl group;
• R3 is selected from H, Cl and alkyl;
• R4 is selected from H and halo;
• R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy;
• R6 is H;
• R7 is selected from CN, haloalkyl, halo, SO2-alkyl, SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH;
• R8 is selected from H, alkyl, haloalkyl and halo;
• R9 is H, alkyl or halo;
• R10 and R11 are each independently H or alkyl;
• and
• R12 and R13 are each independently H or alkyl.